Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
| Market Capitalization | $1441.8363 million |
| P/E Ratio | 24.8 |
| P/E Growth Ratio | 0 |
| Book Value | 0.723 |
| Dividend Per Share | 0 |
| Earnings Per Share | 0.44 |
| EBITDA | 54,760 |
| Profit Margin | 0.7026 |
| Operating Margin TTM | 0.6988 |
| Return on Assets TTM | 0.518 |
| Return on Equity TTM | 0.8806 |
| Revenue TTM | 78,343 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2000-12-31 | 253 | 1,255 | ||
| 2001-12-31 | 178 | 4,783 | ||
| 2002-12-31 | 2,121.35291 | 8,710 | 2,121.35291 | 524.99535 |
| 2003-12-31 | 2,835.76866 | 2,790 | 2,835.76866 | 513.60574 |
| 2004-12-31 | 1,516.52206 | 5,445 | 1,516.52206 | 9,121.28484 |
| 2005-12-31 | 429.66560999999996 | 8,410 | 429.66560999999996 | 10,944.33028 |
| 2006-12-31 | 172.96719000000002 | 10,116 | 172.96719000000002 | 12,351.10556 |
| 2007-12-31 | 944.16065 | 12,327 | 944.16065 | 14,217.016029999999 |
| 2008-12-31 | 2,274.36219 | 11,082 | 2,274.36219 | 12,192.38812 |
| 2009-12-31 | 5,003.23782 | 4,484 | 5,003.23782 | 5,055.852360000001 |
| 2010-12-31 | 4,648.0905 | 9,642 | 4,648.0905 | 9,446.511269999999 |
| 2011-12-31 | 4,150 | 7,194 | 8,251.80677 | |
| 2012-12-31 | 5,333 | 8,230 | 9,478.10914 | |
| 2013-12-31 | 5,658 | 9,751 | -3,859 | 12,360.51108 |
| 2014-12-31 | 2,931 | 10,016 | -7,085 | 12,653 |
| 2015-12-31 | 2,008 | 14,132 | -12,459 | 17,342 |
| 2016-12-31 | 1,494 | 13,325 | -10,175 | 15,247 |
| 2017-12-31 | 47 | 5,136 | -4,505 | 6,782 |
| 2018-12-31 | 13,762 | 6,101 | 7,889 | 8,253 |
| 2019-12-31 | 389 | 9,858 | -9,363 | 11,575 |
| 2020-12-31 | 147 | 9,532 | ||
| 2021-12-31 | 41 | 11,438 | ||
| 2022-12-31 | 14,553 | 14,553 | 16,159 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2000-12-31 | 4,109 | 4,584 | 7,616 | 7,002 | ||
| 2001-12-31 | 3,773 | 5,149 | 16,781 | 15,305 | ||
| 2002-12-31 | 1,928 | 3,332 | 1,509 | |||
| 2003-12-31 | 116 | 696 | 15,413 | 13,724 | ||
| 2004-12-31 | 316.59590000000003 | 12,961.97157 | 4,196.04947 | 19,529.259739999998 | ||
| 2005-12-31 | 23,302.82085 | 35,204.558189999996 | 3,045.95554 | 39,115.44928 | ||
| 2006-12-31 | 9,458.80884 | 19,523.89444 | 3,377.31812 | 13.37375 | 44,528.35235 | |
| 2007-12-31 | 1,137.04421 | 14,586.04897 | 7,035.406019999999 | 3,463.09671 | 28 | 47,580.58834 |
| 2008-12-31 | 1,354.2450900000001 | 8,544.542029999999 | 2,971.97825 | 22.58469 | 11 | 57,522.37558 |
| 2009-12-31 | 3,425.61114 | 10,284.92796 | 2,936.70066 | 8.904 | 490 | 56,130.80784 |
| 2010-12-31 | 1,485.08086 | 5,717.1057599999995 | 2,183.58515 | 454.02779 | 52,280.00911 | |
| 2011-12-31 | 7,488.779 | 11,136.553820000001 | 1,683.52986 | 61,144.16128 | ||
| 2012-12-31 | 5,137.21447 | 8,481.91624 | 2,141.49746 | 64,176.713200000006 | ||
| 2013-12-31 | 24,335.87646 | 26,413.27328 | 2,058.09357 | 101,996.50703000001 | ||
| 2014-12-31 | 20,824 | 22,106 | 3,028 | 104,363 | ||
| 2015-12-31 | 16,642 | 16,904 | 2,502 | 111,912 | ||
| 2016-12-31 | 5,051 | 6,210 | 2,027 | 0 | 112,829 | |
| 2017-12-31 | 4,706 | 17,944 | 1,580 | 9,138 | 121,136 | |
| 2018-12-31 | 23,576 | 26,642 | 1,973 | 0 | 126,426 | |
| 2019-12-31 | 13,844 | 14,406 | 559 | 0 | 126,426 | |
| 2020-12-31 | 24,188 | 24,953 | 753 | 0 | 145,567 | |
| 2021-12-31 | 36,783 | 40,056 | 803 | 0 | 167,578 | |
| 2022-12-31 | 40,180 | 43,267 | 1,678 | 0 | 167,740 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2000-12-31 | ||||||
| 2001-12-31 | 3,505.85393 | |||||
| 2002-12-31 | -5,458.09329 | -5,187.697450000001 | 2,504.18138 | 3,505.85393 | 6,010.035309999999 | |
| 2003-12-31 | -5,647.03824 | -4,678.44956 | -4,332.837519999999 | 5,659.287780000001 | 1,326.45026 | |
| 2004-12-31 | -5,694.11113 | -3,678.23519 | -975.6322700000001 | 1,292.2281699999999 | 316.59590000000003 | |
| 2005-12-31 | -8,308.42518 | -8,392.490189999999 | 11,354.380720000001 | 320.38109000000003 | 11,674.76182 | |
| 2006-12-31 | -10,115.90585 | -9,140.513550000001 | -1,685.0927199999999 | 11,143.90157 | 9,458.80884 | |
| 2007-12-31 | -12,152.54536 | -11,502.55417 | -8,206.79937 | 9,343.84358 | 1,137.04421 | |
| 2008-12-31 | -15,419.48975 | -9,040.568800000001 | 274.36219 | 1,079.8828899999999 | 1,354.2450900000001 | |
| 2009-12-31 | 99.56289 | -1,287.03254 | 2,115.10442 | 1,310.5067199999999 | 3,425.61114 | |
| 2010-12-31 | -4,893.32625 | -2,873.73776 | -1,728.03887 | 3,213.11973 | 1,485.08086 | |
| 2011-12-31 | -4,650.43743 | 6,000.76075 | 1,488.01826 | 7,488.779 | ||
| 2012-12-31 | -5,093.59137 | -2,949.7144700000003 | -2,670.52665 | 7,807.74112 | 5,137.21447 | |
| 2013-12-31 | -11,298.83261 | -7,709.34829 | 18,382.20425 | 5,953.67221 | 24,335.87646 | |
| 2014-12-31 | -8,297 | -6,410 | -3,555 | 24,379 | 20,824 | |
| 2015-12-31 | -13,397 | -12,731 | -4,182 | 20,824 | 16,642 | |
| 2016-12-31 | -12,014 | -12,378 | -11,591 | 16,642 | 5,051 | 0 |
| 2017-12-31 | 3,288 | -5,590 | -345 | 5,051 | 4,706 | |
| 2018-12-31 | 3,073 | 6,408 | 18,870 | 4,706 | 23,576 | |
| 2019-12-31 | -10,816 | -11,719 | -9,730 | 23,576 | 13,846 | |
| 2020-12-31 | -9,193 | -8,078 | 10,344 | 13,844 | 24,188 | |
| 2021-12-31 | -7,794 | -9,970 | 12,595 | 24,188 | 36,783 | |
| 2022-12-31 | 2,365 | 2,375 | 3,397 | 36,783 | 40,180 |